Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer

Completed · Phase 1

Conditions studied: Cancer

In brief

The purpose of this study is to evaluate the safety and tolerability of IC83/LY2603618 for the treatment of cancer.

Key facts

Study ID

NCT00415636

Run by

Eli Lilly and Company

People needed

31

Starts

2007-01-01

Expected to finish

2010-07-01

Last updated by the study team

2018-10-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has at least one lesion that can be evaluated by Response Evaluation Criteria In Solid Tumors (RECIST)
• Has fully recovered from all toxicities due to the following:
• Local radiation therapy that ended at least 14 days prior to Cycle 1, Day 1.
• Surgery.
• Has a life expectancy of at least 3 months.
• Negative serum pregnancy test.

You may not qualify if…

• Is pregnant or breastfeeding.
• Is a woman of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards.
• Is a man of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards.
• Has a history of brain metastases, unless adequately treated and without radiologic evidence of progressive disease for at least 3 months after completion of therapy.
• Has a known active infection.

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.